Cat. No. 2506
Chemical Name: 2-[[6-Methoxy-4-(1-methylethyl)-1,1
Biological ActivityHigh affinity, potent inhibitor of human leukocyte elastase (HLE) (IC50 = 3.9 nM). Displays species-selectivity (Ki values are 0.017, 1.70, 3.01, 58 and > 100 nM for human, mouse, rat, rabbit and porcine elastase respectively). Inhibits HLE-induced lung hemorrhage in mice (ID50 = 2.8 mg/kg) and reduces infarct size in an in vivo acute model of coronary ischemia-reperfusion injury. Orally active.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Bidouard et al (2003) SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia-reperfusion injury. Eur.J.Pharmacol. 461 49. PMID: 12568915.
Kapui et al (2003) Biochemical and pharmacological characterization of 2-(9-(2-Piperidinoethoxy)-4-oxo-4H-pyrido[1,2-α]pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. J.Pharmacol.Exp.Ther. 305 451. PMID: 12606659.
Varga et al (2003) A novel orally active inhibitor of HLE. Eur.J.Med.Chem. 38 421. PMID: 12750030.
If you know of a relevant citation for this product please let us know.
Keywords: SSR 69071, supplier, Potent, orally, active, human, leukocyte, elastase, inhibitors, Neutrophil, Proteinases, Proteases, SSR69071, HLE, inhibitor
Find multiple products by catalog number
New Products in this Area
Non-peptide, competitive angiotensin converting enzyme (ACE) inhibitorAprotinin
Competitive serine protease inhibitorTCID
Selective ubiquitin C-terminal hydrolase-L3 (UCH-L3) inhibitor2-MPPA
Selective glutamate carboxypeptidase II (GCP II) inhibitor; orally bioavailableE 64
Potent and irreversible cysteine protease inhibitorAEBSF
Broad spectrum, irreversible inhibitor of serine proteasesTC-E 5006
γ-secretase modulator; reduces Aβ42 levelsPTIQ
Potent MMP-3 expression inhibitor; neuroprotective
October 5 - 8, 2014